HCPConnect

For HCPs Only
Recent Clinical Updates
Loading latest clinical updates
Registry Index
Updated Jan 5, 2026Oncogenic Prevention

Vaccine Safety Registry

HPV Vaccine Safety

Evidence-based safety information on HPV vaccines. Clinical data for Gardasil 9, dosing schedules, and long-term surveillance metadata.

Clinical Overview

Professional summary

Human papillomavirus (HPV) is a highly prevalent viral module capable of inducing oncogenic changes. Persistent high-risk HPV infections are the primary drivers of cervical, vaginal, vulvar, penile, anal, and oropharyngeal malignancies.

Registry immunizations are verified to prevent over 90% of cancers associated with specific high-risk viral nodes. Clinical efficacy is maximized when protocols are finalized prior to potential viral exposure.

HPV vaccination prevents more than 90% of virus-induced cancers.
Optimally administered to preteen cohorts prior to potential exposure.
Extensively studied for over 15 years with an exemplary safety profile.
9-valent formulation provides broad protection against high-risk strains.

Available Registry Modules

Vaccine modules

Gardasil 9

Merck & Co. | 9-Valent Protocol

  • Strains protected: HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58.
  • Target cohort: Approved for individuals ages 9-45 years.
  • Indication: Prevention of oncogenic malignancies and condyloma acuminata.
  • Administration: 2 or 3-dose titration based on age at protocol initiation.

View age-specific dosing schedules and titration logic on official nodes.

Eligibility & Schedules

Protocol triage

Routine Protocol

  • Pediatric cohorts (11-12 years)
  • Catch-up immunization through age 26
  • Optional initiation at age 9

Special Triage

  • Adults 27-45: shared clinical decision-making
  • Immunocompromised clinical profiles
  • Men who have sex with men (MSM)

Contraindications

  • Anaphylaxis to previous HPV protocol dose
  • Acute moderate-to-severe febrile illness
  • Gestational status is typically deferred, although not treated as an absolute contraindication

Adverse Reaction Profile

Expected and critical events

Local Reactions

  • Localized pain
  • Erythema
  • Induration (Swelling)

Systemic Profile

  • Pyrexia (Fever)
  • Cephalalgia (Headache)
  • Nausea
  • Generalized fatigue

Emergency Protocol

Syncope and jerking movements can occur post-vaccination, specifically in adolescent cohorts. Implement a 15-minute seated or recumbent observation cycle post-administration.

Safety Metadata Analysis

Monitoring summary

135M+

Doses Distributed

15+ Years

Real-World Data

73,000

Trial Participants

Global Surveillance Synthesis

Independent global reviews by multiple country-specific organizations and the WHO continue to validate the exemplary safety profile and high oncogenic prevention efficacy of HPV registry modules.

Verified Source: CDC / WHO

Last global review: September 1, 2025. Content verified by HCP Connect clinical editorial staff in alignment with 2026 safety protocols.